Published within
|«
«
|
...
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Novartis has finally satisfied Chiron's board after raising its takeover bid for the firm. This is good, if unsurprising, news for Novartis, as Chiron offers the Swiss drug maker growth opportunities in vaccines and biopharmaceuticals. Indeed, despite its recent woes, Chiron should be a good buy, enabling Novartis to become a key player in the increasingly important vaccine market.
Published By Datamonitor
|
02 Nov 2005 |
|
CommentWire
|
Novartis has terminated the development of its pipeline 'super-statin' NKS104 after concluding that it would not be competitive enough to warrant further investment. While this will reduce Novartis' already sparse late-stage cardiovascular pipeline, the move comes as no surprise, especially given the uncertain outlook for the branded statins market, and the growing popularity of non-statin drugs.
Published By Datamonitor
|
20 Dec 2005 |
|
Expert View
|
UK drug manufacturer AstraZeneca ended 2005 on a high note, making four significant acquisitions in December. This spending spree comprised the acquisition of product rights for one phase III drug and two phase II products, alongside the purchase of UK-based biotech firm KuDOS Pharmaceuticals. With these purchases, AstraZeneca aims to bolster its pipeline in both the short and long term.
Published By Datamonitor
|
04 Jan 2006 |
|
Expert View
|
AstraZeneca's SMART is an experimental new regimen for its leading asthma drug Symbicort. A successful approval of this regimen may provide a major incentive to switch patients from GlaxoSmithKline's Seretide and keep new rivals at bay. However, recent labeling changes proposed by the FDA have significant implications for the possibility of future US approvals of variable dosing regimes.
Published By Datamonitor
|
13 Jan 2006 |
|
Expert View
|
Biogenerics - also known as biosimilars or follow-on protein products - are set to become the next big battleground between branded pharma and the generics industry. Biological therapeutics such as epoetin are currently huge money-spinners for big pharma and unsurprisingly, generics players want a slice of the action.
Published By Datamonitor
|
18 Jan 2006 |
|
CommentWire
|
More than two years since its initial approval, Novartis' COX-2 anti-inflammatory Prexige has been launched in the UK. Backed by leading British research and positive data from a number of recent clinical trials, the drug should experience a good uptake in the UK, which will no doubt be reflected across Europe when it hits continental markets this year.
Published By Datamonitor
|
20 Jan 2006 |
|
CommentWire
|
Thanks to Plavix sales and new vaccines launches, Sanofi-Aventis has been able to report impressive sales at a time when big pharma is generally experiencing minimal revenue growth. However, although more product launches are expected this year, with generic competition set to increase Sanofi-Aventis is unlikely to report such encouraging results for 2006 or 2007.
Published By Datamonitor
|
02 Feb 2006 |
|
CommentWire
|
Bayer looks set to face legal action following the release of study results linking the company's blood clot drug Trasylol to adverse events including heart and kidney failure. The study findings, and the potential impacts of litigation, pose a significant threat to Bayer's cardiovascular portfolio, and thus could signal trouble for the company overall.
Published By Datamonitor
|
03 Feb 2006 |
|
CommentWire
|
After a troubling few years, Chiron has posted strong fourth-quarter 2005 sales and profits, driven by the recommencement of Fluvirin sales. These impressive results have boosted the company's share price and gone some way towards restoring confidence, which took a big knock in October 2004 when UK authorities suspended the company's flu vaccine license.
Published By Datamonitor
|
03 Feb 2006 |
|
CommentWire
|
Novartis and Idenix have filed for EU approval of telbivudine in chronic hepatitis B. A European launch would mark Novartis'/Idenix' entry into the chronic hepatitis B market, although, in the long term, the companies are likely to target the Asian market, especially China. However, China's problematic healthcare system and the inability of many patients to afford drugs could impede penetration.
Published By Datamonitor
|
07 Feb 2006 |
|
|«
«
|
...
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.